Tada,

Amazing welcome message and summary of the Zenith connection. I just want to add that the royalty preferred share arrangement of the spin-off was originally arranged to cover all BET bromodomain inhibitor molecules that increased apolipoprotein-AI (apoAI). However, this was amended a while back. From the latest Zenith filings:

"Furthermore, on December 15, 2016, holders of common shares of the Company and holders of common shares of Resverlogix approved amendments to the royalty preferred shares of Resverlogix to remove the requirement that the particular Resverlogix pharmaceutical product elevate plasma levels of certain lipoproteins associated with a decreased risk of atherosclerosis and coronary heart disease; Resverlogix’s Articles of Incorporation were subsequently amended to reflect this amendment."

So now, the royalty preferred shares held by Zenith Capital Corp. will receive royalty from ANY commercialized/profitable Resverlogix molecule. Before it was just for molecules that increased apoAI by a certain level.

At the time of the original spin-off, it seemed that Resverlogix was more the cardio/renal/diabetes/metabolism company and Zenith was going to be more of the oncology/inflammation company. However, both companies have thousands of compounds in their respective BET inhibitor compound libraries. From my recollection, both companies have quite a variety of BET inhibitors with varying specificity for BD1 vs. BD2 and with varying specificity for different BET proteins. Read here for more description of BD/BET protein specificity.

From my understanding, there is very little distinguishing Resverlogix from Zenith except for the current ongoing clinical programs. Resverlogix has ongoing or planned clinical programs in cardio, renal, cognition, Fabrys, pulmonary arterial hypertension, and complement disorders. Zenith has ongoing clinical programs in prostate and breast cancer. However, both companies have a vast library of diverse compounds that may very well hold potential to combat the same diseases. From my understanding, there is nothing stopping from Resverlogix developing their compounds for oncology or inflammation, or stopping Zenith from developing their compounds for cardio/renal/cognition/Fabrys/PAH/compelment. Resverlogix and Zenith are front runners in the field of BET bromodomain inhibitors. If BET bromodomain inhibitors have a future, both of these companies have a HUGE future. Or at least their intellectual property has a HUGE future. 

BDAZ